Results 221 to 230 of about 19,745 (243)
Targeting cancer with bispecific antibodies [PDF]
Science, 2021 Bispecific antibodies might provide off-the-shelf immunotherapeutics for treating ...
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bispecific antibodies for the treatment of hemophilia A
Expert Opinion on Biological Therapy, 2021Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire +3 more sources
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, 1999Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
George J. Weiner +2 more
openaire +2 more sources
Bispecific Antibodies for Thrombolysis
1992The seach of new methods for treatment of “century deseases” such as cancer or atherosclerosis with associated thrombosis sets up a problem of targeting of biologically active substances to localized areas of organism. The use of bifunctional (chimeric) antibodies (particularly - bifunctional monoclonals - biMoAbs) as means of drug targeting becomes a ...
M. Yu. Matveyev +2 more
openaire +2 more sources
Chemical Production of Bispecific Antibodies
2004This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Paul Guptill, Robert F. Graziano
openaire +3 more sources
Bispecific Antibodies as Novel Bioconjugates
Bioconjugate Chemistry, 1998Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two different binding specificities within a single molecule. As ideal bioconjugates, they can specifically glue any two different molecules together without the need for chemical conjugation.
Mavanur R. Suresh, Y Cao
openaire +3 more sources
How to Make Bispecific Antibodies
2000This protocol describes the production of bispecific F(ab')2 antibody derivatives (BsAbs) by the linking of two Fab' fragments via their hinge region SH groups using the bifunctional crosslinker o-phenylenedimaleimide (o-PDM) as described by Glennie et al. (1,2). The procedure is illustrated in Fig. 1.
openaire +3 more sources
Bispecific antibodies in haematological malignancies
Cancer Treatment Reviews, 2018Bispecific antibodies (bsAbs) combine the binding sites of two monoclonal antibodies in one molecule. The close proximity of a tumor specific antigen and an effector cell antigen results in a targeted activation of effector cells. The mechanism is similar to the chimeric antigen receptor (CAR) T-cells, recently approved in two haematologic cancers. CAR
Ralf C. Bargou, Andreas Viardot
openaire +3 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources
Bispecific antibody conjugates in therapeutics
Advanced Drug Delivery Reviews, 2003Bispecific monoclonal antibodies have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-arm structure of bsMAb allows researchers to place a therapeutic agent on one arm while allowing the other to specifically target the disease site.
Ying Cao, Laura Lam
openaire +3 more sources